Vertex's Inaxaplin Shows Kidney Benefit in Additional AMKD Groups; AMPLITUDE Enrollment Complete

Vertex Pharmaceuticals Inc. (VRTX) reported positive Phase 2b results for Inaxaplin in additional patient groups with APOL1-mediated kidney disease (AMKD), while also announcing completion of enrollment in its ongoing Phase 2/3 AMPLITUDE trial. The additional Phase 2b data follow the trial's earlier positive results and support Inaxaplin's continued development in AMKD. The company did not disclose specific efficacy figures or the number of patients evaluated in the expanded analysis. Completion of enrollment in AMPLITUDE, the pivotal Phase 2/3 study, advances the program toward key data readouts. AMKD is a rare, genetic form of kidney disease disproportionately affecting people of recent African ancestry; no approved targeted therapies currently exist for the condition.